@sawroast95
Active 1 year, 1 month ago
Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed to eculizumab.
A retrospective, cohort analysis was performed on the clinical and biomarker […] View
-
Koenig posted an update 1 year, 1 month ago
Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed to eculizumab.
A retrospective, cohort analysis was performed on the clinical and biomarker…[Read more]
-
Koenig became a registered member 1 year, 1 month ago